| 1 |
35050813 | Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. | 2022 Feb |
1 |
| 2 |
35253964 | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. | 2022 Apr |
1 |
| 3 |
35343479 | [Sacubitril/valsartan in oncologic patients with cardiotoxicity: another weapon in our pharmacological armory?] | 2022 Apr |
1 |
| 4 |
35469709 | Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. | 2022 Apr 22 |
2 |
| 5 |
33148948 | TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. | 2021 Jan |
1 |
| 6 |
33189632 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. | 2021 Feb |
1 |
| 7 |
33422508 | Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening! | 2021 Mar 5 |
1 |
| 8 |
33459776 | Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. | 2021 Feb 11 |
1 |
| 9 |
33732669 | Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy. | 2021 |
1 |
| 10 |
33808232 | Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF. | 2021 Mar 30 |
1 |
| 11 |
33822031 | Renal protection in chronic heart failure: focus on sacubitril/valsartan. | 2021 Sep 21 |
1 |
| 12 |
33989294 | Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction? | 2021 |
1 |
| 13 |
34173810 | Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan. | 2021 Sep 1 |
1 |
| 14 |
34216577 | Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. | 2021 Sep 15 |
1 |
| 15 |
34273070 | Current and emerging drug targets in heart failure treatment. | 2021 Jul 17 |
1 |
| 16 |
34612065 | Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. | 2021 Oct 19 |
1 |
| 17 |
34703936 | Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure. | 2021 Oct 8 |
1 |
| 18 |
34859070 | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. | 2021 |
1 |
| 19 |
30776953 | Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia. | 2020 Oct |
1 |
| 20 |
30991886 | Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. | 2020 Aug |
1 |
| 21 |
31028383 | Chronic kidney disease, heart failure and neprilysin inhibition. | 2020 Apr 1 |
1 |
| 22 |
31392960 | Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. | 2020 Jan |
1 |
| 23 |
32319309 | ARNI in cardiovascular disease: current evidence and future perspectives. | 2020 Sep |
1 |
| 24 |
32336521 | When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. | 2020 Mar |
1 |
| 25 |
32348960 | Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. | 2020 May |
1 |
| 26 |
32352509 | Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). | 2020 Jul 1 |
1 |
| 27 |
32370992 | Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry". | 2020 Mar |
1 |
| 28 |
32490351 | Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. | 2020 |
1 |
| 29 |
32648251 | Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. | 2020 |
1 |
| 30 |
32653447 | Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. | 2020 Oct |
1 |
| 31 |
32710603 | Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure. | 2020 Oct |
1 |
| 32 |
32744827 | Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? | 2020 Sep |
1 |
| 33 |
32848403 | Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data. | 2020 |
1 |
| 34 |
32987038 | Neprilysin expression and functions in development, ageing and disease. | 2020 Dec |
2 |
| 35 |
32995716 | Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. | 2020 Sep |
1 |
| 36 |
33004114 | Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. | 2020 Oct |
1 |
| 37 |
33032741 | Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. | 2020 Oct 13 |
1 |
| 38 |
33203141 | The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. | 2020 Nov 15 |
1 |
| 39 |
33224383 | Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. | 2020 Dec |
1 |
| 40 |
33489085 | Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. | 2020 |
1 |
| 41 |
33727901 | The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. | 2020 Nov |
1 |
| 42 |
29450561 | Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study. | 2019 Sep |
2 |
| 43 |
29635392 | Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients? | 2019 Jan 1 |
1 |
| 44 |
29891240 | Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. | 2019 Apr 15 |
1 |
| 45 |
29926350 | Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. | 2019 Feb |
1 |
| 46 |
30420146 | Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. | 2019 Apr 15 |
1 |
| 47 |
30520545 | Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. | 2019 May |
4 |
| 48 |
30679005 | Sacubitril/valsartan: A practical guide. | 2019 May |
1 |
| 49 |
30712431 | Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. | 2019 Feb 5 |
1 |
| 50 |
30895809 | Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35. | 2019 May |
1 |